Novo Nordisk (CPSE:NOVO B) Stock Price Catches On Q3 Earnings Dip

Novo Nordisk stock closed at DKK270.4 after Q3 2026 numbers hit the tape, with traders reacting to the headline wobble in quarterly earnings per share and net profit. On a three month view the share price is still down 11.4%, so short term holders are treating every miss or mixed line as a trading event rather than a business update.

The more important story sits in the longer run profit engine. Trailing twelve month earnings of DKK113.2b and a P/E of 10.5x against higher industry multiples keep the focus on whether this profitability trend and valuation gap can coexist for long.

Love Novo Nordisk's profit engine but unsure how long a 10.5x P/E and that valuation gap can last? Compare it with a curated list of profitable peers in our 203 high quality undervalued stocks

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): DKK 79,195m vs. DKK 74,976m (up about 5.6%)
• Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): DKK 16,740m vs. DKK 20,006m (down about 16.3%)
• Basic EPS (Q3 2026 vs Q3 2025): DKK 3.80 vs. DKK 4.50 (down about 15.6%)
• Products Launched (Q3 2026 vs Q3 2025): 1 product launched vs. 0 products launched and 1 product approved. This reflects a shift from approvals to launches in the quarter.

Novo Nordisk raised 2026 guidance on stronger GLP-1 momentum. Ask Charlie what Novo Nordisk’s new GLP-1 launches really change.

Evaluating Novo Nordisk’s Multi-Blockbuster Ambition Against Q3

The bullish story hangs on Novo Nordisk turning today’s obesity and diabetes strength into a broader, multi-product engine that outlives semaglutide.

"The goal to launch at least five multi-blockbuster drugs by 2030, with a risk adjusted sales ambition of more than DKK 150b over the following decade, gives Novo Nordisk multiple shots at new revenue streams that could lessen reliance on GLP 1 pricing and support longer term earnings resilience."

Q3 moves this claim from slideware toward execution. Adjusted sales of DKK 79.2b and obesity growth of 22% sit alongside concrete milestones. Wegovy pill is live in 7 international markets, Frehemgo has a positive CHMP opinion, and CagriSema plus zenagamtide are advancing. That is early but real progress toward the five multi-blockbuster target.

The price and this Narrative do not agree. → Uncover what this Narrative says Novo Nordisk is actually worth.

Bear Case Check: Novo Nordisk Execution Still Looks Uneven

Bears argue that Novo Nordisk could fall short in replacing future GLP 1 pressure with new franchises if key late stage bets stumble.

"Although Novo Nordisk expects its Blood and Endocrine Disorders unit to grow sales by more than 50% between 2026 and 2030, the setback in the IL-6 cardiovascular programme and the concentration of future expectations in a small number of late stage assets such as FREHEMGO, etavopivat and zaltenibart mean that clinical or regulatory disappointments could leave this diversification short of the pipeline sales needed to counter semaglutide loss of exclusivity and GLP-1 price pressure, with knock on effects for revenue and operating profit."

Q3 revenue growth of about 5.6% and a 27% jump in adjusted operating profit show no sign yet of that earnings hole, helped by obesity volumes and Wegovy pill uptake. At the same time, the ZEUS setback is real, and Frehemgo is still pre launch for 2027, so diversification progress remains more promise than booked sales in these numbers.

Hunt For Quiet Pricing Gaps

Novo Nordisk just showed how a powerful profit engine can still leave investors debating the right multiple. The real opportunity sits in finding stocks that could be mispriced before sentiment shifts.

• Company 1 - 41% below our estimate - uses new leisure centers and a recent platform acquisition to scale a capital-light rollout model.
• Company 2 - 20% below our estimate - converts engineering program wins in regulated sectors into recurring manufacturing work with tighter cash cycle discipline.
• Company 3 - 50% below our estimate - sells oncology planning software that plugs into rivals' hardware and nudges customers toward recurring support contracts.

Three companies from the same screener. Open all 203 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com